{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:16:33Z","timestamp":1789193793429,"version":"build-2803163510"},"reference-count":154,"publisher":"Portland Press Ltd.","issue":"5","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:p>Transthyretin (TTR) amyloidosis (ATTR amyloidosis) is an underdiagnosed and important type\u00a0of cardiomyopathy and\/or polyneuropathy that requires increased awareness within the medical community. Raising awareness among clinicians about this type\u00a0of neuropathy and lethal form of heart disease is critical for improving earlier diagnosis and the identification of patients for treatment. The following review summarizes current criteria used to diagnose both hereditary and wild-type ATTR (ATTRwt) amyloidosis, tools available to clinicians to improve diagnostic accuracy, available and newly developing therapeutics, as well as a brief biochemical and biophysical background of TTR amyloidogenesis.<\/jats:p>","DOI":"10.1042\/cs20160413","type":"journal-article","created":{"date-parts":[[2017,2,18]],"date-time":"2017-02-18T01:10:23Z","timestamp":1487380223000},"page":"395-409","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy"],"prefix":"10.1042","volume":"131","author":[{"given":"Natalie\u00a0J.","family":"Galant","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Department of Medical Biophysics, University of Toronto, TMDT 4-305, 101 College Street, Toronto, Ontario, Canada M5G 1L7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Westermark","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey\u00a0N.","family":"Higaki","sequence":"additional","affiliation":[{"name":"Prothena Biosciences Inc., South San Francisco, CA 94080, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avijit","family":"Chakrabartty","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Department of Medical Biophysics, University of Toronto, TMDT 4-305, 101 College Street, Toronto, Ontario, Canada M5G 1L7"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"key":"2021113010495680500_B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-19294-9","article-title":"Aspects of the history and nomenclature of amyloid and amyloidosis","volume-title":"In Amyloid and Related Disorders, Current Clinical Pathology","author":"Westermark","year":"2015","edition":"2nd edn"},{"key":"2021113010495680500_B2","doi-asserted-by":"publisher","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowzenio","year":"2014","journal-title":"Hum. Mutat."},{"key":"2021113010495680500_B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1568-1637(01)00005-8","article-title":"Sick chaperones and ageing: a perspective","volume":"1","author":"Macario","year":"2002","journal-title":"Ageing Res. Rev."},{"key":"2021113010495680500_B4","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1126\/science.1124646","article-title":"Opposing activities protect against age-onset proteotoxicity","volume":"313","author":"Cohen","year":"2006","journal-title":"Science"},{"key":"2021113010495680500_B5","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/nature02261","article-title":"Protein folding and misfolding","volume":"426","author":"Dobson","year":"2003","journal-title":"Nature"},{"key":"2021113010495680500_B6","first-page":"1808","article-title":"Sur les proprietees optiques de l'amyloide","volume":"97","author":"Divry","year":"1927","journal-title":"Comp. Rend. Soc. Biol. (Paris)"},{"key":"2021113010495680500_B7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"key":"2021113010495680500_B8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3109\/13506129.2015.1054026","article-title":"\u201cGreen (or apple-green)\u201d birefringence of Congo red-stained amyloid","volume":"22","author":"Howie","year":"2015","journal-title":"Amyloid"},{"key":"2021113010495680500_B9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"2021113010495680500_B10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-3083.1979.tb01355.x","article-title":"Senile cardiac amyloidosis: evidence of two different amyloid substances in the ageing heart","volume":"10","author":"Westermark","year":"1979","journal-title":"Scand. J. Immunol."},{"key":"2021113010495680500_B11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am. J. Med."},{"key":"2021113010495680500_B12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1080\/13506120600876757","article-title":"Senile systemic amyloidosis, cerebral amyloid angiopathy, and dementia in a very old Finnish population","volume":"13","author":"Tanskanen","year":"2006","journal-title":"Amyloid"},{"key":"2021113010495680500_B13","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/modpathol.2011.117","article-title":"Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study","volume":"24","author":"Ueda","year":"2011","journal-title":"Mod. Pathol."},{"key":"2021113010495680500_B14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"key":"2021113010495680500_B15","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/1440-1681.12598","article-title":"Effects of transthyretin on thyroxine and \u03b2-amyloid removal from cerebrospinal fluid in mice","volume":"43","author":"Chen","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"2021113010495680500_B16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0167-4838(00)00140-0","article-title":"The transthyretin-retinol-binding protein complex","volume":"1482","author":"Monaco","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"2021113010495680500_B17","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1073\/pnas.091431798","article-title":"Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma","volume":"98","author":"Purkey","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010495680500_B18","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010495680500_B19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.exer.2005.02.003","article-title":"Transthyretin synthesis in rabbit ciliary pigment epithelium","volume":"81","author":"Kawaji","year":"2005","journal-title":"Exp. Eye Res."},{"key":"2021113010495680500_B20","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1600-0420.2007.01098.x","article-title":"Ocular manifestations in liver transplant recipients with familial amyloid polyneuropathy","volume":"86","author":"Sandgren","year":"2008","journal-title":"Acta Ophthalmol."},{"key":"2021113010495680500_B21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/37.1.2642294","article-title":"Transthyretin immunoreactivity in human and porcine liver, choroid plexus, and pancreatic islets","volume":"37","author":"Jacobsson","year":"1989","journal-title":"J. Histochem. Cytochem."},{"key":"2021113010495680500_B22","first-page":"391","article-title":"Senile systemic amyloidosis","volume":"117","author":"Pitk\u00e4nen","year":"1984","journal-title":"Am. J. Path."},{"key":"2021113010495680500_B23","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Plant\u00e9-Bordeneuve","year":"2011","journal-title":"Lancet Neurol"},{"key":"2021113010495680500_B24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/13506129.2003.12088568","article-title":"Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural consideration","volume":"10","author":"Westermark","year":"2003","journal-title":"Amyloid"},{"key":"2021113010495680500_B25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.0954-6820.1982.tb03205.x","article-title":"Renal function in familial amyloidosis with polyneuropathy","volume":"212","author":"Steen","year":"1982","journal-title":"Acta Med. Scand."},{"key":"2021113010495680500_B26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3109\/13506129.2011.574354072","article-title":"Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR)","volume":"18","author":"Wilczek","year":"2011","journal-title":"Amyloid"},{"key":"2021113010495680500_B27","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/jns.12180","article-title":"Transthyretin familial amyloid polyneuropathy (TTR-FAP) in Mallorca: a comparison between late- and early-onset disease","volume":"21","author":"Buades-Rein\u00e9s","year":"2016","journal-title":"J. Peripher. Nerv. Syst."},{"key":"2021113010495680500_B28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","article-title":"Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)","volume":"69","author":"Plant\u00e9-Bordeneuve","year":"2007","journal-title":"Neurology"},{"key":"2021113010495680500_B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/TACG.S19903","article-title":"Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis","volume":"5","author":"Hund","year":"2012","journal-title":"Appl. Clin. Genet."},{"key":"2021113010495680500_B30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.nmd.2016.04.013","article-title":"Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey","volume":"26","author":"Durmu\u015f-Tek\u00e7e","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"2021113010495680500_B31","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.humpath.2011.03.004","article-title":"High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly","volume":"42","author":"Sekijima","year":"2011","journal-title":"Hum. Pathol."},{"key":"2021113010495680500_B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/13506129.2012.750604","article-title":"ATTR amyloid in the carpal tunnel ligament is frequently of wildtype transthyretin origin","volume":"20","author":"Gioeva","year":"2013","journal-title":"Amyloid"},{"key":"2021113010495680500_B33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups. J. Med. Sci."},{"key":"2021113010495680500_B34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/modpathol.2014.102","article-title":"Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis","volume":"28","author":"Yanagisawa","year":"2015","journal-title":"Mod. Pathol."},{"key":"2021113010495680500_B35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0039-6257(95)80025-5","article-title":"Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement","volume":"40","author":"Sandgren","year":"1995","journal-title":"Surv. Ophthalmol."},{"key":"2021113010495680500_B36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/archopht.121.3.351","article-title":"Secondary glaucoma in patients with familial amyloidotic polyneuropathy","volume":"121","author":"Kimura","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"2021113010495680500_B37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/art.1780290323","article-title":"Scalloped pupils in familial amyloid polyneuropathy","volume":"29","author":"Rubinow","year":"1986","journal-title":"Arthritis Rheumatol."},{"key":"2021113010495680500_B38","doi-asserted-by":"publisher","first-page":"e002558","DOI":"10.1161\/CIRCHEARTFAILURE.115.002558","article-title":"Transthyretin cardiac amyloidosis in black Americans","volume":"9","author":"Shah","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"2021113010495680500_B39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"key":"2021113010495680500_B40","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archneur.1968.00470360015001","article-title":"Polyneuritic amyloidosis in a Japanese family","volume":"18","author":"Araki","year":"1968","journal-title":"Arch. Neurol."},{"key":"2021113010495680500_B41","first-page":"1","article-title":"Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden","volume":"590","author":"Andersson","year":"1976","journal-title":"Acta Med. Scand. Suppl."},{"key":"2021113010495680500_B42","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2183\/pjab.86.694","article-title":"Transthyretin-related familial amyloidotic polyneuropathy\u2014Progress in Kumamoto, Japan (1967\u20132010)","volume":"86","author":"Araki","year":"2010","journal-title":"Proc. Jpn. Acad. Ser. B, Phys. Biol. Sci."},{"key":"2021113010495680500_B43","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1469-1809.2008.00439.x","article-title":"On the origin of the transthyretin Val30Met familial amyloid polyneuropathy","volume":"72","author":"Zaros","year":"2008","journal-title":"Ann. Hum. Genet."},{"key":"2021113010495680500_B44","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 Years still the best therapeutic alternative","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"2021113010495680500_B45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS\u2013The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"2021113010495680500_B46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010495680500_B47","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5692\/clinicalneurol.cn-000869","article-title":"Familial amyloid polyneuropathy involving a homozygous Val30Met mutation in the amyloidogenic transthyretin gene presenting with superficial siderosis: a case report","volume":"56","author":"Maetani","year":"2016","journal-title":"Rinsho Shinkeigaku"},{"key":"2021113010495680500_B48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/13506120410001688581","article-title":"Postmortem findings in a familial amyloid polyneuropathy patient with homozygosity of the mutant Val30Met transthyretin gene","volume":"11","author":"Yoshinaga","year":"2004","journal-title":"Amyloid"},{"key":"2021113010495680500_B49","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/jmg.2005.033720","article-title":"Impact of homozygosity for an amyloidogenic transthyretin mutation on phenotype and long term outcome","volume":"42","author":"Holmgren","year":"2005","journal-title":"J. Med. Genet."},{"key":"2021113010495680500_B50","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1365-2796.2003.01173.x","article-title":"Hereditary transthyretin amyloidosis from a Scandinavian perspective","volume":"254","author":"Suhr","year":"2003","journal-title":"J. Intern. Med."},{"key":"2021113010495680500_B51","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-2796.2004.01399.x","article-title":"Discordant penetrance of the trait for familial amyloidotic polyneuropathy in two pairs of monozygotic twins","volume":"256","author":"Holmgren","year":"2004","journal-title":"J. Intern. Med."},{"key":"2021113010495680500_B52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/13506129.2012.673185","article-title":"Cardiac involvement in hereditary-transthyretin related amyloidosis","volume":"19","author":"Rapezzi","year":"2012","journal-title":"Amyloid"},{"key":"2021113010495680500_B53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0002-9343(92)90672-X","article-title":"A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers","volume":"93","author":"Ranlov","year":"1992","journal-title":"Am. J. Med."},{"key":"2021113010495680500_B54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2021113010495680500_B55","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.ahj.2010.02.006","article-title":"Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the arteriosclerosis risk in communities (ARIC) and cardiovascular health (CHS) studies","volume":"159","author":"Buxbaum","year":"2010","journal-title":"Am. Heart J."},{"key":"2021113010495680500_B56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14\u2009333 African-Americans","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"key":"2021113010495680500_B57","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy inpatients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur. Heart J."},{"key":"2021113010495680500_B58","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/path.1759","article-title":"Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology","volume":"206","author":"Bergstr\u00f6m","year":"2005","journal-title":"J. Pathol."},{"key":"2021113010495680500_B59","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00109-010-0695-1","article-title":"Variation in amount of wild-type transthyretin in different fibril and tissue types\u00a0in ATTR amyloidosis","volume":"89","author":"Ihse","year":"2011","journal-title":"J. Mol. Med."},{"key":"2021113010495680500_B60","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3109\/13506129.2013.797890","article-title":"Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis","volume":"20","author":"Ihse","year":"2013","journal-title":"Amyloid"},{"key":"2021113010495680500_B61","doi-asserted-by":"publisher","first-page":"28932","DOI":"10.1074\/jbc.M115.659912","article-title":"Uncovering the mechanism of aggregation of human transthyretin","volume":"290","author":"Saelices","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2021113010495680500_B62","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.bpj.2011.10.009","article-title":"Experimentally derived structural constraints for amyloid fibrils of wild-type transthyretin","volume":"101","author":"Bateman","year":"2011","journal-title":"Biophys. J."},{"key":"2021113010495680500_B63","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1073\/pnas.1317488111","article-title":"Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis","volume":"111","author":"Mangione","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010495680500_B64","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance incardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"key":"2021113010495680500_B65","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","article-title":"Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy","volume":"51","author":"Vogelsberg","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010495680500_B66","doi-asserted-by":"publisher","first-page":"W394","DOI":"10.2214\/AJR.09.3721","article-title":"MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy","volume":"195","author":"Di Bella","year":"2010","journal-title":"Am. J. Roentgenol."},{"key":"2021113010495680500_B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4070\/kcj.2013.43.1.1","article-title":"Advanced cardiac MR imaging for myocardial characterization and quantification: T1 Mapping","volume":"43","author":"Hwang","year":"2013","journal-title":"Korean Circ. J."},{"key":"2021113010495680500_B68","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc. Imaging"},{"key":"2021113010495680500_B69","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/brain\/awu344","article-title":"In\u00a0vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography","volume":"138","author":"Kollmer","year":"2015","journal-title":"Brain"},{"key":"2021113010495680500_B70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","article-title":"(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis","volume":"121","author":"Pilebro","year":"2016","journal-title":"Ups. J. Med. Sci."},{"key":"2021113010495680500_B71","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.111.102053","article-title":"In\u00a0vivo visualization of amyloid deposits in the heart with 11C-PIB and PET","volume":"54","author":"Antoni","year":"2013","journal-title":"J. Nucl. Med."},{"key":"2021113010495680500_B72","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","article-title":"Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot study","volume":"57","author":"Law","year":"2016","journal-title":"J. Nucl. Med."},{"key":"2021113010495680500_B73","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2021113010495680500_B74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/13506129.2013.871250","article-title":"Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis","volume":"21","author":"Glaudemans","year":"2014","journal-title":"Amyloid"},{"key":"2021113010495680500_B75","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt","year":"2014","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"2021113010495680500_B76","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-016-0638-5","article-title":"Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR)","author":"Pilebro","year":"2016","journal-title":"J. Nucl. Cardiol."},{"key":"2021113010495680500_B77","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur. Heart J."},{"key":"2021113010495680500_B78","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.jacc.2009.12.040","article-title":"Infiltrative cardiovascular diseases: cardiomyopathies that look alike","volume":"55","author":"Seward","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010495680500_B79","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.pcad.2009.11.007","article-title":"Amyloid heart disease","volume":"52","author":"Falk","year":"2010","journal-title":"Prog. Cardiovasc. Dis."},{"key":"2021113010495680500_B80","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.0954-6820.1987.tb01243.x","article-title":"Differentiation of cardiac amyloidosis and hypertrophic cardiomyopathy. A comparison of familial amyloidosis with polyneuropathy and hypertrophic cardiomyopathy by electrocardiography and echocardiography","volume":"221","author":"Eriksson","year":"1987","journal-title":"Acta Med. Scand."},{"key":"2021113010495680500_B81","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.hlc.2011.06.002","article-title":"Left atrial size\u2013another differentiator for cardiac amyloidosis","volume":"20","author":"Fitzgerald","year":"2011","journal-title":"Heart Lung Circ."},{"key":"2021113010495680500_B82","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/S0140-6736(98)02361-7","article-title":"New concept in echocardiography: harmonic imaging of tissue without use of contrast agent","volume":"352","author":"Caidahl","year":"1998","journal-title":"Lancet"},{"key":"2021113010495680500_B83","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.4065\/73.11.1062","article-title":"Image enhancement by noncontrast harmonic echocardiography. Part I. Qualitative assessment of endocardial visualization","volume":"73","author":"Mulvagh","year":"1998","journal-title":"Mayo Clin. Proc."},{"key":"2021113010495680500_B84","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1253\/circj.CJ-16-0364","article-title":"Left atrial morphology, size and function in patients with transthyretin cardiac amyloidosis and primary hypertrophic cardiomyopathy\u2013comparative strain imaging study","volume":"80","author":"de Gregorio","year":"2016","journal-title":"Circ. J."},{"key":"2021113010495680500_B85","doi-asserted-by":"publisher","first-page":"e000289","DOI":"10.1136\/openhrt-2015-000289","article-title":"Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy","volume":"3","author":"Damy","year":"2016","journal-title":"Open Heart"},{"key":"2021113010495680500_B86","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.amjcard.2004.10.028","article-title":"Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement","volume":"95","author":"Murtagh","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"2021113010495680500_B87","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.amjmed.2015.05.039","article-title":"Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology","volume":"128","author":"Maurer","year":"2015","journal-title":"Am. J. Med."},{"key":"2021113010495680500_B88","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.107.743427","article-title":"Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period","volume":"118","author":"Holzmann","year":"2008","journal-title":"Circulation"},{"key":"2021113010495680500_B89","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.ajpath.2016.02.020","article-title":"Overexpression of protocadherin-10\u00a0in transthyretin-related familial amyloidotic polyneuropathy","volume":"186","author":"Gon\u00e7alves","year":"2016","journal-title":"Am. J. Pathol."},{"key":"2021113010495680500_B90","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2459\/JCM.0000000000000349","article-title":"Different NT-proBNP circulating levels for different types\u00a0of cardiac amyloidosis","volume":"17","author":"Perfetto","year":"2016","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"2021113010495680500_B91","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12872-016-0311-6","article-title":"Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis","volume":"16","author":"Zhao","year":"2016","journal-title":"BMC Cardiovasc. Disord."},{"key":"2021113010495680500_B92","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","article-title":"Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis","volume":"341","author":"Holmgren","year":"1993","journal-title":"Lancet"},{"key":"2021113010495680500_B93","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","article-title":"Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)","volume":"40","author":"Holmgren","year":"1991","journal-title":"Clin. Genet."},{"key":"2021113010495680500_B94","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00007890-199807270-00016","article-title":"Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis","volume":"66","author":"Stangou","year":"1998","journal-title":"Transplantation"},{"key":"2021113010495680500_B95","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/13506120701614032","article-title":"Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation","volume":"14","author":"Liepnieks","year":"2007","journal-title":"Amyloid"},{"key":"2021113010495680500_B96","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/00007890-199707150-00014","article-title":"Progression of ventricular wall thickening after liver transplantation for familial amyloidosis","volume":"64","author":"Dubrey","year":"1997","journal-title":"Transplantation"},{"key":"2021113010495680500_B97","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.lts.2003.09.016","article-title":"Outcome of liver transplantation for familial amyloidotic polyneuropathy","volume":"9","author":"Sharma","year":"2003","journal-title":"Liver Transpl."},{"key":"2021113010495680500_B98","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/00007890-200203150-00015","article-title":"Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type","volume":"73","author":"Olofsson","year":"2002","journal-title":"Transplantation"},{"key":"2021113010495680500_B99","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/BF00294304","article-title":"Drainage of molecules from subarachnoid space to spinal nerve roots and peripheral nerve of the rat. A study based on Evans blue-albumin and lanthanum as tracers","volume":"86","author":"Pettersson","year":"1993","journal-title":"Acta Neuropathol."},{"key":"2021113010495680500_B100","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1212\/WNL.0000000000003001","article-title":"Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis","volume":"87","author":"Sekijima","year":"2016","journal-title":"Neurology"},{"key":"2021113010495680500_B101","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","article-title":"CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings","volume":"86","author":"Maia","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2021113010495680500_B102","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/bmj.309.6962.1135","article-title":"Cardiac transplantation for AL amyloidosis","volume":"309","author":"Hall","year":"1994","journal-title":"BMJ"},{"key":"2021113010495680500_B103","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.healun.2004.08.025","article-title":"Outcome of heart transplantation in patients with amyloid cardiomyopathy","volume":"24","author":"Kpodonu","year":"2005","journal-title":"J. Heart Lung Transplant."},{"key":"2021113010495680500_B104","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1136\/heart.85.2.202","article-title":"Long term results of heart transplantation in patients with amyloid heart disease","volume":"85","author":"Dubrey","year":"2001","journal-title":"Heart"},{"key":"2021113010495680500_B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol. Ther."},{"key":"2021113010495680500_B106","doi-asserted-by":"publisher","first-page":"12119","DOI":"10.1021\/bi00096a024","article-title":"Transthyretin mutation Leu-55-Pro alters tetrameric stability and increases amyloidogenicity","volume":"32","author":"McCutchen","year":"1993","journal-title":"Biochemistry"},{"key":"2021113010495680500_B107","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010495680500_B108","doi-asserted-by":"publisher","first-page":"97ra81","DOI":"10.1126\/scitranslmed.3002473","article-title":"Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity","volume":"3","author":"Alhamadsheh","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"2021113010495680500_B109","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","article-title":"Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy","volume":"23","author":"Waddington Cruz","year":"2016","journal-title":"Amyloid"},{"key":"2021113010495680500_B110","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"2021113010495680500_B111","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0272-2712(18)30427-X","article-title":"Thyroid hormone transport proteins","volume":"13","author":"Bartalena","year":"1993","journal-title":"Clin. Lab. Med."},{"key":"2021113010495680500_B112","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1016\/j.febslet.2009.10.062","article-title":"Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity","volume":"583","author":"Ferreira","year":"2009","journal-title":"FEBS Lett."},{"key":"2021113010495680500_B113","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.febslet.2011.06.030","article-title":"Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation","volume":"585","author":"Ferreira","year":"2011","journal-title":"FEBS Lett."},{"key":"2021113010495680500_B114","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/13506129.2012.668502","article-title":"Natural polyphenols as modulators of TTR amyloidogenesis: in\u00a0vitro and in\u00a0vivo evidences towards therapy","volume":"19","author":"Ferreira","year":"2012","journal-title":"Amyloid"},{"key":"2021113010495680500_B115","doi-asserted-by":"publisher","first-page":"26623","DOI":"10.1038\/srep26623","article-title":"Curcumin: a multi-target disease-modifying agent for late-stage transthyretin amyloidosis","volume":"6","author":"Ferreira","year":"2016","journal-title":"Sci. Rep."},{"key":"2021113010495680500_B116","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2119\/molmed.2016.00124","article-title":"Resveratrol administration increases transthyretin protein levels ameliorating AD features\u2013importance of transthyretin tetrameric stability","volume":"22","author":"Santos","year":"2016","journal-title":"Mol. Med."},{"key":"2021113010495680500_B117","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1124\/dmd.104.000885","article-title":"High absorption but very low bioavailability of oral resveratrol in humans","volume":"32","author":"Walle","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"2021113010495680500_B118","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jns.2014.07.017","article-title":"Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area","volume":"345","author":"Takahashi","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"2021113010495680500_B119","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"key":"2021113010495680500_B120","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/archinte.160.6.777","article-title":"Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem","volume":"160","author":"Page","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"2021113010495680500_B121","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010495680500_B122","doi-asserted-by":"publisher","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant'Anna","year":"2016","journal-title":"Nat. Commun."},{"key":"2021113010495680500_B123","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J. Transl. Med."},{"key":"2021113010495680500_B124","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbadis.2008.05.005","article-title":"Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy","volume":"1782","author":"Macedo","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"2021113010495680500_B125","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1042\/CS20160075","article-title":"Impairment of autophagy by TTR V30M aggregates: in\u00a0vivo reversal by TUDCA and curcumin","volume":"130","author":"Teixeira","year":"2016","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113010495680500_B126","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB J."},{"key":"2021113010495680500_B127","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2014.12.003","article-title":"Polymer-doxycycline conjugates as fibril disrupters: an approach towards the treatment of a rare amyloidotic disease","volume":"198","author":"Conejos-S\u00e1nchez","year":"2015","journal-title":"J. Control. Release"},{"key":"2021113010495680500_B128","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","article-title":"Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid"},{"key":"2021113010495680500_B129","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2021113010495680500_B130","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann. Med."},{"key":"2021113010495680500_B131","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"key":"2021113010495680500_B132","doi-asserted-by":"publisher","first-page":"e52686","DOI":"10.1371\/journal.pone.0052686","article-title":"AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils","volume":"7","author":"Wall","year":"2012","journal-title":"PLoS One"},{"key":"2021113010495680500_B133","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001\u00a0in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2021113010495680500_B134","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","article-title":"2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis","volume":"23","author":"Renz","year":"2016","journal-title":"Amyloid"},{"key":"2021113010495680500_B135","doi-asserted-by":"publisher","first-page":"25080","DOI":"10.1038\/srep25080","article-title":"Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses","volume":"6","author":"Galant","year":"2016","journal-title":"Sci. Rep."},{"key":"2021113010495680500_B136","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid"},{"key":"2021113010495680500_B137","doi-asserted-by":"publisher","first-page":"25096","DOI":"10.1074\/jbc.M116.738138","article-title":"Novel antibody for the treatment of transthyretin amyloidosis","volume":"291","author":"Hosoi","year":"2016","journal-title":"J. Biol. Chem."},{"key":"2021113010495680500_B138","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2021113010495680500_B139","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature09494","article-title":"Antibodies to human serum amyloid P component eliminate visceral amyloid deposits","volume":"468","author":"Bodin","year":"2010","journal-title":"Nature"},{"key":"2021113010495680500_B140","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0022-2836(78)90368-6","article-title":"Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 \u00c5","volume":"121","author":"Blake","year":"1978","journal-title":"J. Mol. Biol."},{"key":"2021113010495680500_B141","doi-asserted-by":"publisher","first-page":"27207","DOI":"10.1074\/jbc.M101024200","article-title":"Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants","volume":"276","author":"Quintas","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2021113010495680500_B142","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3109\/13506129409148451","article-title":"A chemical approach to elucidate the mechanism of transthyretin and \u03b2-protein amyloid fibril formation","volume":"1","author":"Kelly","year":"1994","journal-title":"Amyloid"},{"key":"2021113010495680500_B143","doi-asserted-by":"publisher","first-page":"6470","DOI":"10.1021\/bi952501g","article-title":"The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid","volume":"35","author":"Lai","year":"1996","journal-title":"Biochemistry"},{"key":"2021113010495680500_B144","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jmb.2008.07.029","article-title":"Structural insight into pH-induced conformational changes within the native human transthyretin tetramer","volume":"382","author":"Palaninathan","year":"2008","journal-title":"J. Mol. Biol."},{"key":"2021113010495680500_B145","doi-asserted-by":"publisher","first-page":"11442","DOI":"10.1021\/bi011194d","article-title":"An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured","volume":"40","author":"Jiang","year":"2001","journal-title":"Biochemistry"},{"key":"2021113010495680500_B146","doi-asserted-by":"publisher","first-page":"14943","DOI":"10.1073\/pnas.261419998","article-title":"The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis","volume":"98","author":"Jiang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010495680500_B147","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modifications of transthyretin modulate its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","journal-title":"Biochemistry"},{"key":"2021113010495680500_B148","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/0006-291X(91)91687-8","article-title":"Normal transthyretin and synthetic transthyretin fragments form amyloid-like fibrils in\u00a0vitro","volume":"175","author":"Gustavsson","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113010495680500_B149","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1021\/bi3002727","article-title":"Specific disruption of transthyretin (105\u2013115) fibrilization using \u201cstabilizing\u201d inhibitors of transthyretin amyloidogenesis","volume":"51","author":"Liang","year":"2012","journal-title":"Biochemistry"},{"key":"2021113010495680500_B150","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1074\/jbc.M310605200","article-title":"Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy","volume":"279","author":"Olofsson","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021113010495680500_B151","doi-asserted-by":"publisher","first-page":"28324","DOI":"10.1074\/jbc.M114.563981","article-title":"The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses","volume":"289","author":"Sant'Anna","year":"2014","journal-title":"J. Biol. Chem."},{"key":"2021113010495680500_B152","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1073\/pnas.1101194108","article-title":"Heparan sulfate\/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein","volume":"108","author":"Noborn","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010495680500_B153","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1021\/bi010655s","article-title":"Identification of a subunit interface in transthyretin amyloid fibrils: evidence for self-assembly from oligomeric building blocks","volume":"40","author":"Serag","year":"2001","journal-title":"Biochemistry"},{"key":"2021113010495680500_B154","doi-asserted-by":"publisher","first-page":"15525","DOI":"10.1021\/bi051608t","article-title":"The pathway by which the tetrameric protein transthyretin dissociates","volume":"44","author":"Foss","year":"2005","journal-title":"Biochemistry"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/131\/5\/395\/445238\/cs1310395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/131\/5\/395\/445238\/cs1310395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:39:23Z","timestamp":1638272363000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/131\/5\/395\/71584\/Transthyretin-amyloidosis-an-under-recognized"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":154,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20160413","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,17]]}}}